Dynavax (DVAX) Receives $27M Vaccine Purchase Order from CDC


(NEW YORK)–Dynavax Technologies Corp (NASDAQ: DVAX) receives $27.4 million contract purchase order from CDC for adult vaccines.

DVAX receives a purchase contract from the Centers of Disease Control (CDC) for $27.4 million for adult vaccines. Some of the vaccines purchased by the CDC were:

Hepatitis A adult vaccine
Pneumococcal Polysaccharide vaccine
Pneumococcal Conjugate (PCV13) vaccine
Measles, Mumps, and Rubella vaccine
Human Papillomavirus (HPV9) vaccine
Serogroup B Meningococcal vaccine

The vaccines awarded under these contracts will be purchased for NCIRD’s immunization awardees (the fifty state health departments, several large city programs and current and former U.S. Territories) to support adult immunization programs as provided under the Public Health Service Act.

COVID-19 Vaccine Program

What makes this a positive for DVAX is that is shows their experience and current established relationship with agencies like the CDC and FDA in not only developing but supplying vaccines for the commercial market.

DVAX announced that its collaboration partner, Clover Biopharmaceuticals, has begun a phase I study on its COVID-19 vaccine candidate that contains Dynavax’s CpG 1018 adjuvant.

An adjuvant helps to enhance the immune response of an antigen leading to rapid development of the vaccine and broader availability to patients. An adjuvanted vaccine may also help patients with chronic conditions and less responsive to vaccination.

There are many COVID-19 vaccine plays that have caught the attention of traders, such as Moderna (MRNA) Inovio Pharmaceuticals (INO) and Novavax (NVAX). What brings DVAX to this group is their experience and expertise in working with FDA and CDC in developing vaccines, and more important the manufacturing capabilities which can be just as important when reviewing plays that could make it.

DVAX sock has been rising in recent weeks and is primed to break above its key $10 mark, which could set the stage for faster move up to $15 before pausing to consolidate.

About Dynavax

Dynavax Technologies Corporation, a biopharmaceutical company, focuses on leveraging the power of the body’s innate and adaptive immune responses through toll-like receptor stimulation. The company markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in adults age 18 years and older. Its immuno-oncology portfolio includes development stage products, such as SD-101 and DV281. Dynavax Technologies Corporation has a research collaboration with Clover Biopharmaceuticals; the University of Queensland and the Coalition for Epidemic Preparedness; and Sinovac Biotech Ltd. for the development of a vaccine candidate to prevent coronavirus (COVID-19). Dynavax Technologies Corporation has partnership with the Coalition for Epidemic Preparedness Innovations (CEPI) to create a vaccine against COVID-19 infection; and a collaboration with Valneva SE to initiate a vaccine program for the coronavirus, COVID-19.

This is NOT a solicitation to Buy or Sell any security, but rather is for informational purposes only. Content contained herein includes facts, views, opinions and recommendations of individuals and organizations deemed of interest. Wall Street Newscast (“WSNC”) does not guarantee the accuracy, completeness or timeliness of, or otherwise endorse these views, opinions or recommendations, or give investment advice. In Compliance with SEC Rule 17B WSNC was not compensated for this media alert. WSNC, or any of its affiliates, holds no positions in securities mentioned above. These investments may involve a high degree of risk, thus investors are highly encouraged to consult with a financial adviser before any and all investments.
Safe Harbor Statements:
This website includes statements that may constitute forward-looking statements made pursuant to the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. Although the Company believes that the expectations reflected in such forward-looking statements are based on reasonable assumptions, such statements are subject to risks and uncertainties that could cause actual results to differ materially from those projected.
High Risk
Small and Micro cap, or ‘penny stocks’, involve a high degree of risk, and we highly encourage investors to consult with a financial adviser before making any and all investment decisions when investing in these type of securities